Cemdisiran, an under-the-skin injection therapy given every three months, significantly reduced disease activity in people with generalized myasthenia gravis (gMG) after six months of treatment. That’s according to data from […] The post Cemdisiran significantly eases disease activity in gMG adults appeared first on Myasthenia Gravis News.
